RxDoctor Payments Data

Relvert Coe, MD

Internal Medicine · Palestine, TXNPI 1215946637

Payments from drug & device makers

$307in general payments, 2019–2025

Across 15 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$93
  • Amgen$59
  • Novo Nordisk$43
  • AbbVie$40
  • AstraZeneca$31
  • Boehringer Ingelheim$17
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$307 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$225,043
Medicare patients
137
Services billed
7,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$55,917
MounjaroTirzepatide48$54,624
OzempicSemaglutide41$42,535
JardianceEmpagliflozin27$33,383
FarxigaDapagliflozin Propanediol21$22,247
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,131
TrulicityDulaglutide11$12,921
Tresiba Flextouch U-100Insulin Degludec15$6,602
TrintellixVortioxetine Hydrobromide12$5,385
Breo ElliptaFluticasone/Vilanterol11$4,261
Potassium Chloride110$4,105
Rosuvastatin Calcium187$2,707
CombipatchEstradiol/Norethindrone Acet11$2,624
Omeprazole184$2,506
Omega-3 Acid Ethyl Esters34$2,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$42,53541 claims
Boehringer IngelheimJardiance$17$33,38327 claims
AstraZenecaFarxiga$31$22,24721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Palestine

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →